Sarepta: Time to Chase? – Barron’s

Barron’s

Sarepta: Time to Chase?
Barron’s
We’ve updated our EXONDYS 51 patient calculator, and even based on conservative assumptions around new patient starts for 2H17, and assuming some positive impact to Q2 revenues by an early bolus of start forms and patients in the que, updated …

and more »

Leave a Reply

Your email address will not be published. Required fields are marked *

*

3 × two =